BindingDB logo
myBDB logout

25 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
26222319 192 Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.EBI Nerviano Medical Sciences Srl
26183543 87 Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.EBI University of Oulu
24527792 8 Design, synthesis, crystallographic studies, and preliminary biological appraisal of new substituted triazolo[4,3-b]pyridazin-8-amine derivatives as tankyrase inhibitors.EBI Universit£ degli Studi di Perugia
24294969 2 Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.EBI Amgen Inc.
24116873 16 Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity.EBI University of Oulu
23879431 11 Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrases.EBI Novartis Institutes for Biomedical Research Incorporated
23844574 71 Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor.EBI Novartis Institutes for Biomedical Research
23701517 12 Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.EBI Amgen Inc.
23672613 8 Fragment-based ligand design of novel potent inhibitors of tankyrases.EBI Nanyang Technological University
23316926 12 Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket.EBI Amgen Inc.
22233320 19 Structural basis of selective inhibition of human tankyrases.EBI Abo Akademi University
22260203 73 [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.EBI Novartis Institutes for Biomedical Research
20364863 30 Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic.EBI Johns Hopkins University Brain Science Institute
19873981 34 Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.EBI IRBM/Merck Research Labs Rome
20337371 79 Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.EBI Abbott Laboratories
20015648 94 Discovery and SAR of novel, potent and selective hexahydrobenzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).EBI IRBM-Merck Research Laboratories Rome
19553107 27 Identification of aminoethyl pyrrolo dihydroisoquinolinones as novel poly(ADP-ribose) polymerase-1 inhibitors.EBI IRBM--Merck Research Laboratories Rome
27667561 16 Small-Molecule Chemical Probe Rescues Cells from Mono-ADP-Ribosyltransferase ARTD10/PARP10-Induced Apoptosis and Sensitizes Cancer Cells to DNA Damage.BDB University of Oulu